Li Zefeng, Ren Hu, Zhang Xiaojie, Sun Chongyuan, Fei He, Li Zheng, Guo Chunguang, Shi Susheng, Chen Yingtai, Zhao Dongbing
Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 PanjiayuanNanli, Chaoyang District, Beijing 100021, China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 PanjiayuanNanli, Chaoyang District, Beijing 100021, China.
J Clin Med. 2023 Sep 18;12(18):6039. doi: 10.3390/jcm12186039.
According to the 2019 World Health Organization (WHO) classification of gastric neuroendocrine neoplasms, gastric neuroendocrine carcinoma (GNEC) can be further divided into gastric large-cell neuroendocrine carcinoma (GLNEC) and gastric small-cell neuroendocrine carcinoma (GSNEC). Whether the prognoses of the two types have a discrepancy has long been disputed.
We collected patients diagnosed with GLNEC or GSNEC in the National Cancer Center of China between January 2000 and December 2020. The characteristics and survival outcomes were compared between the two groups. We further verified our conclusion using the SEER dataset.
A total of 114 GNEC patients, including 82 patients with GLNEC and 32 patients with GSNEC, have completed treatment in our hospital. Clinicopathologic differences were not observed between patients with GSNEC and GLNEC concerning the sex, age, body mass index, Charlson Comorbidity Index, tumor location, tumor size, stage, treatment received, the expression of neuroendocrine markers (CD56, Chromogranin A, synaptophysin), and score on the Ki-67 index. The 1-year, 3-year, and 5-year overall survival rates of GLNEC and GSNEC were 89.0%, 60.5%, and 52.4%, and 93.8%, 56.3%, and 52.7%, which showed no statistically significant differences. This result was confirmed further by using the SEER dataset after the inverse probability of treatment weighting.
Although with different cell morphology, the comparison of prognosis between the GLNEC and GSNEC has no significant statistical difference.
根据2019年世界卫生组织（WHO）胃神经内分泌肿瘤分类，胃神经内分泌癌（GNEC）可进一步分为胃大细胞神经内分泌癌（GLNEC）和胃小细胞神经内分泌癌（GSNEC）。长期以来，这两种类型的预后是否存在差异一直存在争议。
我们收集了2000年1月至2020年12月在中国国家癌症中心诊断为GLNEC或GSNEC的患者。比较两组患者的特征和生存结局。我们使用监测、流行病学和最终结果（SEER）数据集进一步验证了我们的结论。
共有114例GNEC患者在我院完成治疗，其中包括82例GLNEC患者和32例GSNEC患者。GSNEC和GLNEC患者在性别、年龄、体重指数、查尔森合并症指数、肿瘤位置、肿瘤大小、分期、接受的治疗、神经内分泌标志物（CD56、嗜铬粒蛋白A、突触素）的表达以及Ki-67指数评分方面未观察到临床病理差异。GLNEC和GSNEC的1年、3年和5年总生存率分别为89.0%、[60.5%]和52.4%，以及93.8%、56.3%和52.7%，差异无统计学意义。在进行治疗权重逆概率分析后，使用SEER数据集进一步证实了这一结果。
尽管细胞形态不同，但GLNEC和GSNEC的预后比较无显著统计学差异。
